Welcome to the Radboudumc what are you looking for?
A considerably higher dose of the anti-tuberculosis drug rifampicin is safe and can also lead to a shorter treatment for tuberculosis and less resistance.
In severe COVID-19 patients the lung tissue recovers well in most cases. This is shown in research by the Radboudumc, published in Clinical Infectious Diseases. Striking conclusion: patients who were referred by the general practitioner recover worse than ICU patients.
Radboudumc researchers are the only ones in the Netherlands using a new method to make better lung cancer diagnoses earlier stage. Erik van der Heijden and Roel Verhoeven shows that the use of flexible imaging equipment via the natural respiratory tract contributes to a more accurate diagnosis.
The first multicenter study by researchers Roel Verhoeven and Erik van der Heijden, in which the added predictive value of elastography by means of endobronchial ultrasound of mediastinal lymph nodes in patients with lung cancer was systematically investigated.
Martin Boeree is searching for shorter and better treatments for drug sensitive and resistant tuberculosis. He is also conducting interdisciplinary research on treatment and clinical relevance in the area of non-tuberculous mycobacteria.
For more than 40 years, patients with tuberculosis have been prescribed almost the same dose of rifampicin. Some studies suggest that the dose is too low and not optimal.
In Clinical Infectious Diseases Elin Svensson and colleagues showed that increasing rifampicin exposure shortened the time needed to reach undetectable levels of bacteria in sputum.
One of the Sustainable Development Goals is a world without tuberculosis in 2030.
This website uses cookies. Read more about cookies.